本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑 9 l) v+ Z5 j) Z+ d
, E" s* P9 X1 j' zclinicaltrials上的三期临床链接
+ N7 f1 h `6 i. [ E3 ~3 d7 V6 a5 I7 v9 e& u/ R- Y" p- V
http://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn( a& @9 v4 N7 ~3 C3 x% z
4 Y A( h X+ X/ v( L2 Y
中国参加临床实验的城市
8 o& x: M' q+ X
9 m& m( x# T" r* GChina, Guangdong 6 i! j2 \1 B/ _- g5 z ^ @
+ b2 n# l6 p) w% G" v: n
Guangzhou, Guangdong, China, 510515 3 i* A. ?% P% p4 k* `
0 F4 A. A, d. N! @, O: OGuangzhou, Guangdong, China, 510060
$ ]9 v% P2 O) G2 u; w. j; ?& c) nChina, Jiangsu
6 f( x, B- d2 Y0 y/ T+ e1 G! q4 ]0 @
S' g5 N; N) d0 _5 WNanjing, Jiangsu, China, 210009 5 ~% B. R, E E3 V& C
- w+ V# X& V/ [4 SNanjing, Jiangsu, China, 210002 4 X7 Z$ u' C8 n2 [7 {/ u \
China, Shandong
% F2 p9 c% u/ H0 q* o : A* D/ ^0 {! K4 |9 u
Qingdao, Shandong, China, 266003
: u: w z. d8 S& F& x8 bChina
: S* }0 N5 k; p6 R) e5 ^- C1 E ! H! y! ~8 B% P" e6 @
Beijing, China, 100021
% R; x! \# ]0 d7 i3 O 1 `- s+ Z0 X' L7 e5 U; V( E
Beijing, China, 100071 - ~9 T1 g' u( v# h5 q
" d3 G9 u0 L% Y. W4 p4 E; gChangchun, China, 130021
i) S! h( @& U; y8 R: m; e$ y ) ^# ?& T% _& E1 i
Chongqing, China, 400042 5 x# p0 T" x, X) e0 I& }6 U+ L
6 A M1 c: l- U# [+ B% e
Chongqing, China, 400038 ( I" C* ?+ C7 H3 a: T1 s
7 k( w8 p: ^! E" f( D+ ]
Fuzhou, China, 350014
& X9 P, ^* R9 K' q9 \1 h 1 O/ k; Y0 X \; Y% z
Fuzhou, China, 350025 * x% q, ~# Y* K0 X1 K i
+ E& v- `2 \: w& j4 zHa'erbin, China, 150040
) a" N/ \1 T. y( o, K2 l5 U" i 8 j" N& C$ p7 R* P, E
Hanghzou, China, 310009 - x/ x- g% u2 P9 G/ X
# w9 i( m; ^- i4 E. @) OShanghai, China, 200001 6 }# `" S5 p9 z
" ?3 e4 O; f; @& c0 Z3 e
Shanghai, China, 200030
& {' ?0 J* j7 p7 l, o& i
2 I6 p* j1 b' v+ q3 }Tianjin, China
* v, @4 S4 J' M* Y! ^! M# J* `1 j/ x4 P; X% o* x" p
该实验已停止招募,重新开的临床请见临床专用贴。 |